Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Price:
14.2
CNY
-2.54%
Market Closed
Market Cap:
¥7.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
|
CN |
|
BNP Paribas SA
PAR:BNP
|
FR |
|
C
|
Campbell Soup Co
SWB:CSC
|
US |
|
H
|
Hydrogene De France SA
PAR:HDF
|
FR |
|
Johnson Service Group PLC
LSE:JSG
|
UK |
|
S
|
Shenzhen FRD Science & Technology Co Ltd
SZSE:300602
|
CN |
|
Abundante Ltd
SGX:570
|
SG |
|
Corporacion Acciona Energias Renovables SA
MAD:ANE
|
ES |
|
Bega Cheese Ltd
ASX:BGA
|
AU |
|
G
|
Greenland Resources Inc
OTC:GRLRF
|
CA |
|
Chang Hwa Commercial Bank Ltd
TWSE:2801
|
TW |
|
S
|
STWC Holdings Inc
OTC:STWC
|
US |
|
H
|
Highlands REIT Inc
OTC:HHDS
|
US |
|
S
|
Shengjing Bank Co Ltd
HKEX:2066
|
CN |
|
Spirax-Sarco Engineering PLC
LSE:SPX
|
UK |
Multiples-Based Value
The Multiples-Based Value of one
Hunan Jiudian Pharmaceutical Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 14.2 CNY,
Hunan Jiudian Pharmaceutical Co Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Hunan Jiudian Pharmaceutical Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Hunan Jiudian Pharmaceutical Co Ltd Competitors
Hunan Jiudian Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
|
7.1B CNY | 2.3 | 15.1 | 12.8 | 12.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 13.4 | 42.4 | 28.6 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 6.2 | 21.6 | 15 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.2B USD | 2.5 | 20.4 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.4B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
